Takei, Jun
Kamata, Yuko
Tanaka, Toshihide
Fukasawa, Nei
Gomisawa, Kazutaka
Satake, Mari
Mori, Ryosuke
Yamamoto, Yohei
Suzuki, Tomoya
Oda, Ayaka
Murahashi, Mutsunori
Fukuda, Takahiro
Shimoda, Masayuki
Murayama, Yuichi
Akasaki, Yasuharu
Funding for this research was provided by:
the Ministry of Education, Culture, Sports, Science and Technology and the Japan Society for Promotion of Science (21K09161)
Article History
Received: 12 March 2023
Accepted: 13 June 2023
First Online: 29 June 2023
Declarations
:
: The authors have no relevant financial or non-financial interests to disclose.
: Approval was granted by the Institutional Review Board of Jikei University School of Medicine [permission numbers: 30-137(9158) and 16-184(4412)]. Trial approval was granted by the Institutional Review Board of Jikei University School of Medicine (Trial registration ID: 16-184-4412).
: Written informed consent was obtained from all patients receiving TFDC therapy. In addition, we employed an opt-out method approved by the institutional review board to obtain consent for this retrospective study using a notice posted on our institutional homepage.